Advertisement
U.S. markets closed

Atai Life Sciences N.V. (ATAI)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.6700-0.1000 (-5.65%)
At close: 04:00PM EDT
1.7000 +0.03 (+1.80%)
After hours: 07:38PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close1.7700
Open1.7900
Bid2.0200 x 2900
Ask2.1200 x 2900
Day's Range1.6100 - 1.7900
52 Week Range1.0250 - 2.3900
Volume1,589,176
Avg. Volume1,499,990
Market Cap277.237M
Beta (5Y Monthly)0.96
PE Ratio (TTM)N/A
EPS (TTM)-0.4300
Earnings DateMar 19, 2024 - Mar 26, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.62
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ATAI

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • ATAI Life Sciences N.V.
    Daily – Vickers Top Buyers & Sellers for 03/31/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    last yearArgus Research
View more
  • News Direct

    atai Life Sciences advances VLS-01 for treatment-resistant depression

    atai Life Sciences chief scientific officer Dr Srinivas Rao discusses the company's development candidate VLS-01, aimed at treating treatment-resistant depression, with Proactive's Stephen Gunnion.

  • GlobeNewswire

    atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01

    The Phase 1b trial of VLS-01 investigates the pharmacokinetics, pharmacodynamics, safety and tolerability of atai’s proprietary, optimized oral transmucosal formulation of DMTVLS-01 is being developed as a rapid-acting and durable antidepressant for treatment resistant depression, which affects approximately 100 million people globallyVLS-01 is designed to induce a short psychedelic experience, allowing for a total in-clinic treatment of 2-hours, consistent with an established commercial paradig

  • GlobeNewswire

    atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conference

    NEW YORK and BERLIN, Feb. 28, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that management will participate in a panel discussion at the TD Cowen conference in Boston, MA, at 12:50pm ET on March 4, 2024. A live audio webcast of the panel discussion will be available on the Investors section of the atai website under Events. A replay of the webcast will